Treatment of inflammatory bowel disease
AssigneesEli Lilly and Company, London Hospital Medical College
InventorsDavid Blake, Peter P. K. Ho, Jill A. Panetta, David Rampton, Nicola Simmonds
Life of this patent
Estimating the term…
Abstract
Inflammatory bowel disease is treated, and patients are protected from a relapse into active disease, by the administration of a compound chosen from a series of 3-phenyl-5-carboxypyrazoles and isothiazoles.
Claims19
A method for treating or preventing the recurrence of inflammatory bowel disease comprising administering to a patient in need thereof an effective dose of a compound of the formula ##STR2## wherein X is a sulfur atom, a nitrogen atom, or a methyl-substituted nitrogen atom;
- R is hydrogen, amino, C.sub.1 -C.sub.3 alkylamino, or hydroxy;
- R.sup.1 is hydroxy, or OM;
- M is a nontoxic cation;
- R.sup.2 and R.sup.3 independently represent hydrogen, halo, C.sub.1 -C.sub.3 alkyl, trifluoromethyl, or C.sub.1 -C.sub.3 alkoxy.
A suppository or enema mixture formulation adapted for rectal administration comprising an effective amount of a compound of the formula ##STR3## wherein X is a sulfur atom, a nitrogen atom, or a methyl-substituted nitrogen atom;
- R is hydrogen, amino, C.sub.1 -C.sub.3 alkylamino, or hydroxy;
- R.sup.1 is hydroxy, or OM;
- M is a nontoxic cation;
- R.sup.2 and R.sup.3 independently represent hydrogen, halo, C.sub.1 -C.sub.3 alkyl, trifluoromethyl, or C.sub.1 -C.sub.3 alkoxy.
Dependencies are inferred from the claim text.